Actively Recruiting
Phase I Study Evaluating Safety and Activity of SSS59 in Patients with Advanced Malignant Tumors
Led by Shenyang Sunshine Pharmaceutical Co., LTD. · Updated on 2025-04-29
154
Participants Needed
1
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, pharmacokinetics, and antitumor activity of SSS59, a humanized antibody targeting MUC17, in patients with advanced malignant tumors. This open-label phase I study is designed to understand how this drug behaves in the body and its effects on tumors in patients with advanced, recurrent, or metastatic cancers who have failed or cannot tolerate standard therapies. The study consists of four parts Part A1 and Part A2 involve dose escalation and extension with weekly and every two weeks intravenous administration, respectively. Part A3 includes dose extension with dosing every three weeks, and Part B focuses on indication extension in certain tumor types such as advanced gastric or gastroesophageal junction adenocarcinoma expressing MUC17. Dose escalation follows specific designs, including accelerated titration and 33 traditional methods, across multiple dose levels to identify the maximum tolerated dose and recommended dose. Participants will undergo regular safety and tolerability assessments during treatment and up to 28 days after the last dose, with long-term follow-up for dose-limiting toxicities over 21 days and monitoring through study completion. Researchers will measure drug levels, pharmacodynamics, immunogenicity, and preliminary antitumor effects at various points. The study requires patients to have adequate organ function and an ECOG performance status of 0-1, with expected survival over three months. Total participation may last about two years for outcome evaluation.
CONDITIONS
Brief Title
A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors
Research Team
Q
Qi Li, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here